Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in... | May 1, 2023

Related Keywords

United States ,China ,Taiwan ,Hong Kong ,Macau ,Meg Alexander ,Eli Lilly ,Samuel Waksal ,Jeremy Levin ,Durho ,Imclone Systems ,Kadmon Pharmaceuticals ,Corporate Affairs ,Ovid Therapeutics Inc ,Nasdaq ,Graviton Bioscience Corporation ,Exchange Commission ,Equilibre Biopharmaceuticals Corp ,Ovid Therapeutics ,New York Based ,Bioscience Corporation ,Equilibre Biopharmaceuticals ,Annual Report ,Ovid Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Collaboration ,O ,Unlock ,The ,Herapeutic ,Potential ,F ,Rock2 ,Inhibition ,Or ,Mare ,Neurological ,Diseases ,Couples ,David ,Capabilities ,N ,Ns ,Development ,Ith ,Xpertise Ovid Us6904691010 ,